Eiger Biopharmaceuticals Garners $7,100,000 Series A Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=317f5e1c-2973-46e5-b80d-1e361e7b0b91&Preview=1 -
Date
2/24/2009 -
Company Name
Eiger Biopharmaceuticals -
Mailing Address
3350 West Bayshore Road Palo Alto, CA 94303 -
Company Description
Eiger BioPharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger’s pipeline includes repurposed clinical agents as well as preclinical new chemical entities (NCEs) from its discovery research shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. -
Website
http://www.eigerbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$7,100,000 -
Transaction Round
Series A -
Proceeds Purposes
The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets. -
M&A Terms
-
Venture Investor
InterWest Partners -
Venture Investor
Vivo Ventures
